Illumina, Inc. (ETR:ILU)
Germany · Delayed Price · Currency is EUR | Market Cap | 18.74B +74.4% |
| Revenue (ttm) | 3.81B +1.3% |
| Net Income | 740.40M |
| EPS | 4.79 |
| Shares Out | n/a |
| PE Ratio | 25.30 |
| Forward PE | 26.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242 |
| Average Volume | 149 |
| Open | 125.02 |
| Previous Close | 122.94 |
| Day's Range | 123.96 - 125.92 |
| 52-Week Range | 69.28 - 132.16 |
| Beta | 1.13 |
| RSI | 69.08 |
| Earnings Date | Apr 30, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
What CEOs from Tesla, Nvidia and over a dozen other companies hope to gain by joining Trump in China
A key part of President Donald Trump's visit to China this week is his effort to bring along with him at least 17 executives from prominent U.S. companies. Here's what it means for them.
Illumina price target raised to $95 from $80 at Citi
Citi raised the firm’s price target on Illumina (ILMN) to $95 from $80 and keeps a Sell rating on the shares.
Illumina price target raised to $125 from $120 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Illumina (ILMN) to $125 from $120 and keeps a Neutral rating on the shares.
Illumina price target raised to $155 from $150 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Illumina (ILMN) to $155 from $150 and keeps an Outperform rating on the shares.
Illumina price target lowered to $140 from $150 at Canaccord
Canaccord lowered the firm’s price target on Illumina (ILMN) to $140 from $150 and keeps a Hold rating on the shares. The firm said the target decrease is driven by…
Illumina price target raised to $122 from $110 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $122 from $110 and keeps an Underweight rating on the shares. The company reported a big instrument upside surprise in…
Illumina Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong clinical growth and robust NovaSeq X demand, prompting raised full-year guidance for revenue, margin, and EPS. Clinical markets remain the primary growth driver, while research and applied markets are cautious amid funding uncertainty.
Illumina reports Q1 adjusted EPS $1.15, consensus $1.05
Reports Q1 revenue $1.09B, consensus $1.07B. “Illumina (ILMN) delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy,” said Jacob Thaysen, Ch...
Illumina raises FY26 adjusted EPS view to $5.15-$5.30 from $5.05-$5.20
FY26 consensus $5.12. Raises FY26 revenue view to $4.52B-$4.62B from $4.5B-$4.6B, consensus $4.54B.
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 202...
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalizati...
Illumina and D3b announce partnership for research in pediatric diseases
Illumina (ILMN) and the Center for Data-Driven Discovery in Biomedicine, or D3b, announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platfor...
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center f...
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. O...
Illumina announces board changes
Illumina (ILMN) announced changes to its Board of Directors. Frances Arnold, PhD, Robert Epstein, MD, and Gary Guthart, PhD, will retire from the Board in connection with the company’s upcoming…
Illumina Announces Changes to Board of Directors
David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S.
Labcorp, Illumina expand collaboration to broaden access to oncology testing
Illumina (ILMN) and Labcorp (LH) announced an expanded collaboration to advance precision oncology through applications of next-generation sequencing solutions across the healthcare ecosystem. Project...
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collabo...
Illumina announces strategic collaboration with Veritas Genetics
Illumina (ILMN) announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health ins...
Illumina advances preventive genomics through strategic consortium with Veritas Genetics
New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- ...
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, Mar...
Illumina Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted ongoing innovation in sequencing platforms, new product launches like TruPath, and advancements in spatial and proteomics technologies. Financial guidance remains conservative but optimistic, with clinical growth outpacing research and a focus on delivering end-to-end solutions and actionable insights.
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NA...
Roche genome pricing positive for Illumina, says TD Cowen
TD Cowen analyst Dan Brennan says Roche (RHHBY) yesterday announced the consumables price for the Xpandomer-based nanopore sequencer, Axelios, at $150 per genome duplex. Expectations had crept down to...
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026
SAN JOSE, Calif.--(BUSINESS WIRE)-- #NGS--Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.